We are a leading life sciences investor financing highly innovative companies worldwide.
We provide biotech ventures with the resources to develop novel therapies for indications with high unmet medical needs.
We invest in companies that will have a positive impact on patients and society.
The scientific, financial and entrepreneurial
expertise of our international team has proven
instrumental to the development of many thriving
We are united by our commitment to achieving
success for new, promising companies.
Our portfolio features an exciting mix of biotech
companies located across Europe and the United
States, all of which have a high potential to make
a meaningful impact.
CVRx® developed a proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim neo uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. Barostim neo can be adjusted to meet each patient’s individual therapy needs.
Galecto is focused on developing novel drugs for the treatment of fibrosis, inflammation, and cancer based on targeting galectins, a group of proteins shown to be involved in many disease processes. Galecto’s team of scientists and experts has shown in preclinical and clinical studies that the company’s high potency galectin modulators may open new treatment possibilities for many patients. The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in Phase II/III studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen, Denmark.
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary mucus-penetrating particle technology, with a focus on the treatment of eye diseases. Kala’s first product, INVELTYS® for the treatment of inflammation and pain following ocular surgery, was approved in 2019 and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease is in phase III trials
Minoryx is a clinical-stage biotech company developing new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program leriglitazone (MIN-102) has completed a Phase II/III clinical trial for the treatment of adrenomyeloneuropathy, the most common phenotype of X-linked Adrenoleukodystrophy, and a Phase II study in Friedreich’s Ataxia.
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, founded in 2016, that is specialized in the discovery and development of therapeutic proteins for the prevention and treatment of bleeding. The company’s leading product in development, VMX-C001, is a new therapeutic protein to prevent or stop severe bleeding in patients taking blood thinners in the form of direct factor Xa inhibitors.
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases including Wilson Disease, Progressive Familiar Intrahepatic Cholestasis (PFIC) and other indications. Vivet is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression.
First safety data expected in 2023 with full read-out expected in 2025
The offering is expected to close on or about December 5, 2022, subject to customary closing conditions.
Key clinical data from Target-HTN demonstrated clinically meaningful efficacy in the treatment of patients with uncontrolled and resistant hypertension
The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).